Background {#Sec1}
==========

As carbapenems are among the most reliable therapeutic options for treating *Pseudomonas aeruginosa* infection, the finding of carbapenem resistance is an ominous development that challenges this "last resort antibiotic". Production of metallo-β-lactamases (MBLs) is an important mechanism of carbapenem resistance, not only because MBLs can hydrolyse most β-lactams including carbapenems, but MBL-producing *P. aeruginosa* are frequently also multidrug-resistant (resistant to ≥ 3 classes) \[[@CR1]\]. More importantly, *bla*~MBL~ genes are often located in the gene cassette (GC) arrays in integrons, where multiple resistant determinants against antimicrobials or disinfectants are accumulated, and can be horizontally transferred \[[@CR2]\].

Multilocus sequence typing (MLST), a genotyping method based on nucleotide sequencing of several house-keeping genes in the bacterial chromosome, has been increasingly applied for epidemiological investigation of pathogenic microorganisms \[[@CR3]\]. In *P. aeruginosa* isolates, international clones such as ST (sequence type) 235, ST244, ST175, and ST357 are reported to have widespread dissemination \[[@CR4]-[@CR11]\]. Most notably, ST235 and their close variants (e.g., clonal complex 235) appear prominent in multiple-drug resistance.

Recently, the INTEGRALL database was developed for providing a systematic nomenclature for integrons \[[@CR12]\]; these genetic elements can be potentially shared by a wide range of microorganisms as a result of horizontal gene transfer \[[@CR13]\]. Moreover, GC arrays of integrons could be excised or integrated by the action of integrases and therefore be more diverse \[[@CR2]\]. Therefore, INTEGRALL is expected to facilitate our comprehensive understanding of the complexity and development of integron-mediated drug resistance.

In Japan, as many as 80-90% of the MBL-producing *P. aeruginosa* were reported to be resistant to carbapenems, aminoglycosides, and quinolones \[[@CR14],[@CR15]\]. Notably, several molecular epidemiological surveys report the increasing prevalence of multidrug-resistant *P. aeruginosa* (MDRP); in these the predominance of IMP-type MBL genes as well as ST235 and ST357 among MDRP is documented \[[@CR15]-[@CR20]\]. Although the prevalence of MBL among *P. aeruginosa* clinical isolates was reported as 2-4% \[[@CR21],[@CR22]\], molecular epidemiology of MBL-producing *P. aeruginosa* in consecutive nationwide surveillance programs has not been analysed.

In the current study, we conducted a molecular epidemiological survey of the genetic context of MBL-producing *P. aeruginosa* isolates collected by nationwide surveillance. Our data not only provide an important "snapshot" of the molecular characteristics and dynamics of MBL-producing predominant lineages including ST235 and ST357, but also provide important baseline information for future surveillance programs. (This work was presented in part at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2011.)

Results and discussion {#Sec2}
======================

Antimicrobial susceptibility of MBL-producing *P. aeruginosa* isolates {#Sec3}
----------------------------------------------------------------------

In the present study, 44 MBL-producing *P. aeruginosa* isolates were identified (Table [1](#Tab1){ref-type="table"}); these were recovered from 6 out of 8 geographic regions across Japan. The number of isolates is comparable in 2004 and in 2006. MBL-producers were isolated more frequently from urinary tract specimens than from other specimens (24/408 vs. 20/1580; *P* \< 0.0001). Although this trend was consistent with the previous reports in Japan \[[@CR23]\], the reason for preference of MBL-producers for urinary tract was not addressed in this study where we did not analyse non-MBL-producers.Table 1**Distribution of metallo-β-lactamase-producing** ***Pseudomonas aeruginosa*** **across clinical specimens in the present study** ^**a**^**Year of isolationClinical specimens'04'06**Urinary tract9/188 (0.9%)15/220 (1.5%)Respiratory tract2/491 (0.2%)2/449 (0.2%)Gastrointestinal tract1/33 (0.1%)2/62 (0.2%)Blood and fluids2/73 (0.2%)0/41 (0%)Others9/211 (0.9%)2/220 (0.2%)Total23/996 (2.3%)21/992 (2.1%)^a^shown as a number of metallo-β-lactamase-producing *P. aeruginosa* isolates divided by a number of all *P. aeruginosa* isolates.

All MBL-producers met the international criteria for MDRP (Table [2](#Tab2){ref-type="table"}). Overall, the antibiotic resistance patterns of MBL-producers did not differ significantly among the isolates between 2004 and 2006, except in cases where piperacillin was tested (4/23 resistant to piperacillin in 2004 vs 16/21 in 2006; *P* = 0.0002). Although this result reinforces the impact of the MBL production in MDRP, their limited susceptibility to the entire armamentarium of β-lactams including piperacillin or aztreonam, which MBLs are expected to hydrolyse less efficiently, suggests the involvement of multiple factors contributing to their drug resistance \[[@CR24]\].Table 2**Profiles of metallo-β-lactamase-producing** ***Pseudomonas aeruginosa*** **in this studyNo.YearLocationSpecimensPFGESTIntegronMIC (μg/ml)TUMNoGC arraysPIPCCAZCFPMAZTIPMAMKABKCPFX**40462004ShikokuUrineA1070In113*bla* ~IMP-1~ \| *aacA28* \| *aadA1*32\>512\>5123251225641639862006KantoUrineC235(partial)^a^*bla* ~IMP-7~ ^a^128512256864\>512321639952006KantoUrineC235(partial)^a^*bla* ~IMP-7~ ^a^256\>512256864\>512641639972006KantoPurulent dischargeC235(partial)^a^*bla* ~IMP-7~ ^a^8\>5122564512\>512643239882006KinkiUrineA235In113*bla* ~IMP-1~ \| *aacA28* \| *aadA1a*256\>512\>512646425623239772006HokkaidoFecesB235In113*bla* ~IMP-1~ \| *aacA28* \| *aadA1a*2565125126412825623239782006ChugokuDrainB235In113*bla* ~IMP-1~ \| *aacA28* \| *aadA1a*256512256166425643239842006KantoUrineB235In113*bla* ~IMP-1~ \| *aacA28* \| *aadA1a*2565122561664\>5122\>12839892006ChugokuUrineB235In113*bla* ~IMP-1~ \| *aacA28* \| *aadA1a*256\>512\>5126464\>51243239902006KantoSputumB235In113*bla* ~IMP-1~ \| *aacA28* \| *aadA1a*128\>512256864\>5124\>12839912006KantoUrineB235In113*bla* ~IMP-1~ \| *aacA28* \| *aadA1a*256512256864\>5124\>12839942006KantoUrineB235In113*bla* ~IMP-1~ \| *aacA28* \| *aadA1a*12851225632512\>51223240292004HokkaidoFecesB235In113*bla* ~IMP-1~ \| *aacA28* \| *aadA1a*322562561625612811640342004KantoPurulent dischargeB235In113*bla* ~IMP-1~ \| *aacA28* \| *aadA1a*128\>51225616128\>51241640352004ChugokuUrineB235In113*bla* ~IMP-1~ \| *aacA28* \| *aadA1a*512\>512512326425621640312004KantoPurulent dischargeB235In915*bla* ~IMP-6~ \| *aacA28* \| *aadA1a*6412812816\>512\>51243239932006ShikokuUrineB235In829*bla* ~IMP-10~ \| *aacA28* \| *aadA1a*16\>512512\>5122561282\>12840362004KantoUrineB235In829*bla* ~IMP-10~ \| *aacA28* \| *aadA1a*256\>51225616512\>51243239922006ChugokuUrineD357In994*bla* ~IMP-1~32\>512\>51264128641\>12840332004ChugokuUrineD357In994*bla* ~IMP-1~64\>512\>5123251280.5\>12840382004ChugokuPurulent dischargeD357In994*bla* ~IMP-1~64\>512\>5122562568≤0.253240392004ChugokuUrineD357In994*bla* ~IMP-1~32\>512\>5122562568≤0.256440402004ChugokuUrineD357In994*bla* ~IMP-1~1651251264256641\>12840412004ChugokuPurulent dischargeD357In994*bla* ~IMP-1~1651251264\>5122561\>12840422004ChugokuUrineD357In994*bla* ~IMP-1~1651251232256641\>12840432004ChugokuFecesD357In994*bla* ~IMP-1~1651251232\>5122560.5\>12840442004ChugokuSputumD357In994*bla* ~IMP-1~3251251264\>5122561\>12840452004ChugokuUrineD357In994*bla* ~IMP-1~3251251264128641\>12839962006ChugokuPharyngeal mucusD357In995*bla* ~IMP-10~8\>512\>51232256641\>12839792006ShikokuUrineD357In826*aacA7* \| *fosI* \| *bla* ~IMP-41~ \| *qacG*8\>51251282562568\>12839852006KantoFecesD357In991*aacA7* \| *bla* ~IMP-11~ \| *bla* ~OXA-2~ \| *qacG*256\>51225686412821640492004KyusyuUrineE357In833*bla* ~IMP-6~ \| *fosE*264644328≤0.25840472004KyusyuPurulent dischargeF244In994*bla* ~IMP-1~6451212884\>51232\>12840482004KyusyuPurulent dischargeF244In994*bla* ~IMP-1~6451212884\>51232\>12840372004KinkiUrineF244In832*fosE* \| *aacA31* \| *bla* ~VIM-2~64641616\>51225611639802006KyusyuUrineG244In993*bla* ~IMP-10~ \| *aadA2* \| *bla* ~OXA-47b~128\>51251216816≤0.253240282004HokkaidoUrineH277In994*bla* ~IMP-1~512\>512\>51264256160.5\>12840302004HokkaidoUrineH277In831*bla* ~IMP-10~ \| *aacA1*, *gcuG*16\>512\>51264\>512\>51283240272004HokkaidoSputumI186In830*bla* ~IMP-1~ \| *aacA4′-3* \| *aacA1*, *gcuG* \| *aadA1a*325121281641288839812006KyusyuUrineJ175In827*bla* ~IMP-1~ \| *aacA4′-3* \| *aacA4′-3* \| *catB6* \| *bla* ~CARB-12~512\>512\>5121282561284\>12839822006KyusyuUrineJ175In827*bla* ~IMP-1~ \| *aacA4′-3* \| *aacA4′-3* \| *catB6* \| *bla* ~CARB-12~\>512\>512\>5121282566443239832006KyusyuUrineJ175In827*bla* ~IMP-1~ \| *aacA4′-3* \| *aacA4′-3* \| *catB6* \| *bla* ~CARB-12~512\>512\>5121282566483240322004KantoBloodJ308In992*aacA7* \| *bla* ~IMP-1~16\>51251216256320.5839872006KyusyuUrineK360In828*bla* ~IMP-1~ \| *aadA24*, *aacA4′-3*1282561283264128232PFGE, pulsed-field gel electrophoresis; ST, sequence type; PIPC, piperacillin; CAZ, ceftazidime; CFPM, cefepime; AZT, aztreonam; IPM, imipenem; AMK, amikacin; ABK, arbekacin; CPFX, ciprofloxacin.^a^3′-conserved segment (3'CS) was unknown and therefore no integron number was attributed.

Acknowledging that CLSI breakpoints were not available, the majority of MBL-producers showed increased susceptibility to arbekacin (MIC \>8 μg/ml in only 5 strains, 11%). Although further investigation is needed, this agent might be a candidate for consideration as a therapeutic agent \[[@CR25]\]. For more than two decades in Japan, arbekacin is a commercially available aminoglycoside effective against methicillin-resistant *Staphylococcus aureus* infections and its use in Gram negative infections is being explored .

MBL genes and class 1 integrons among MBL-producing *P. aeruginosa* {#Sec4}
-------------------------------------------------------------------

Among MBL-producing *P. aeruginosa* isolates, seven different MBL genes were identified. The most prevalent was *bla*~IMP-1~ group found in 38 isolates (80%) (31 *bla*~IMP-1~, 5 *bla*~IMP-10~, and 2 *bla*~IMP-6~), followed by 3 *bla*~IMP-7~, 2 *bla*~IMP-11~ group (1 *bla*~IMP-11~ and 1 *bla*~IMP-41~), and 1 *bla*~VIM-1~, as anticipated (Table [2](#Tab2){ref-type="table"}) \[[@CR15]-[@CR19]\]. While *bla*~IMP-1~ and *bla*~IMP-10~ were found both in 2004 and 2006, *bla*~IMP-7~, *bla*~IMP-11~, and *bla*~IMP-41~ emerged in 2006.

All MBL-producing isolates possessed *intI1*, and all MBL genes were located in the GC arrays of class 1 integron (Table [2](#Tab2){ref-type="table"}); 16 distinct MBL-harboring integrons were identified. Complete GC arrays of all integrons except one were successfully sequenced, as many as 13 of which were novel to INTEGALL database. Fifteen isolates harbored In113-like integrons, which consisted of 3 GCs, namely *bla*~IMP-1~ group cassette (*bla*~IMP-1~ in In113, *bla*~IMP-6~ in In915, and *bla*~IMP-10~ in In829) followed by *aacA28* and *aacA1a* GCs. Similarly, thirteen isolates harbored In994-like integrons which contains a sole *bla*~IMP-1~ group cassette (*bla*~IMP-1~ in In994 and *bla*~IMP-10~ in In995). The family of *bla*~MBL~ genes and their position in integron GC arrays did not show significant differences in resistance profile (Table [2](#Tab2){ref-type="table"}).

Genotypes and their relationship with integrons among MBL-producing *P. aeruginosa* {#Sec5}
-----------------------------------------------------------------------------------

Among MBL-producing *P. aeruginosa* isolates, nine different STs were identified by MLST: the most prevalent was ST235 (17 isolates, 39%) followed by ST357 (14 isolates, 32%) and ST244 (4 isolates, 9%) (Table [2](#Tab2){ref-type="table"}). While these major 3 STs were found both in 2004 and 2006, the other 6 STs were found either in 2004 or in 2006.

Most integrons distributed in the specific genotypes of the isolates. In113-like integrons were found in ST235/pulsotype B isolates with significantly high frequency (13/13 vs 2/31; *P* \< 0.0001), while partial *bla*~IMP-7~-harboring integron was exclusively found in ST235/pulsotype C (3/3 vs 0/41; *P* \< 0.0001). While distributed across 5 geographic regions in total, ST235 was significantly associated with Kanto region (10/12 vs 7/32; *P* = 0.0003). ST235 was also associated with resistance to piperacillin (13/17 vs 7/27; *P* = 0.0017). Although not significant, a trend of increased ST235 in 2006 was observed (5/23 in 2004 vs 12/21 in 2006; *P* = 0.0291).

MBL-producing ST235 isolates seemed the dominant MDRP lineage in Japan as also reported worldwide \[[@CR6],[@CR8]-[@CR11],[@CR13]\]. As ST235 isolates are described as harboring a variety of resistance determinants including integrons, its diverse geographic distribution across Japan reflects part of the worldwide dissemination. Especially, isolates of ST235/pulsotype B with In113-like integron, recovered from 3 regions in the present study, were well characterized as a representative of the MDRP in Japan \[[@CR15],[@CR16],[@CR19]\].

In our analysis, ST357 was significantly associated with In994-like integrons (11/14 vs. 3/30, *P* \< 0.0001). ST357 is another widely disseminated lineage also found in the present study \[[@CR4],[@CR7],[@CR16]\]. Concurrently, ST357 was found in Chugoku region with significantly higher frequency (11/14 vs 3/30, *P* \< 0.0001), which might possibly reflect local transmission. However, ST357 harbored 5 different integrons in total, including 2 with *bla*~IMP-11~ group GCs emerged in 2006 (In826 and In991).

The significant association of specific genotypes and integrons implies that, in a relatively short period of time, dissemination and transmission of the preexisting resistant lineage, rather than horizontal gene transfer or recombination *in situ*, might largely explain their endemicity. Moreover, the genotypes of MBL-producers were unexpectedly similar to those in the central Europe with different resistant determinants, suggesting their possible advantage beyond other genotypes in the clinical settings \[[@CR4]\]. Although the isolate number was small, the present study elucidated the emergence of ST357 isolates with novel integrons in distant geographic regions in 2006, as well as an emergence of the ST235/pulsotype C with partial integron harboring *bla*~IMP-7~ in Kanto region, which might suggest the increased complexity of endemic lineages. In addition, isolates with ST175 was recovered in Kyushu with significantly higher frequency (3/3 vs 5/41, *P* = 0.0042).

One of the limitations of the present study is that this is retrospective in nature and therefore the results are not expected to be directly applied to the current clinical situation. There are also several reports in Japan addressing a variety of integron structures of *P. aeruginosa* \[[@CR15]-[@CR20]\], and they seemed to contain identical or similar integrons to ones identified in the current study. Nevertheless, the findings here are important, since most of the integron structures were novel to INTEGRALL database \[[@CR12]\]; this could be explained by the lack of comprehensive platform for integron structure and nomenclature before the development of INTEGRALL database until recently. Alternatively, this might reflect true heterogeneity and diversity of the integrons among clinical isolates, especially among non-predominant lineages. Moreover, MLST comparison of cross-sectional nationwide survey is much informative for understanding of the dynamics of drug-resistant organisms. In addition, this is the first report of the presence of novel *fosI* gene cassette other than *Mycobacterium* spp. \[[@CR26]\], and further analysis regarding the actual transfer route beyond the boundary of the species is warranted. As genotyping including MLST and INTEGRALL has been increasingly applied for tracking the development of the drug resistance rationally, the data in the present study would provide a robust baseline to estimate the current trend and future diversification of the drug-resistant lineages \[[@CR20]\]. Another shortcoming of this study is that horizontal gene transfer of *bla*~MLB~ genes, possibly located on plasmid or chromosome, was not experimentally addressed.

Conclusions {#Sec6}
===========

The current study offers an important "snapshot" of the molecular characteristics and dynamics of MBL-producing *P. aeruginosa* lineages including ST235 and ST357 across Japan and provide critical information for the design and implementation of surveillance programs targeted to the discovery of multidrug resistant *P. aeruginosa*.

Methods {#Sec7}
=======

Bacterial isolates {#Sec8}
------------------

A total of 1,988 *P. aeruginosa* isolates (996 isolates in 2004 and 992 in 2006), were retrospectively collected as a part of nationwide surveillance programs in Japan (Japan Antimicrobial Resistance Surveillance Participants Group) \[[@CR27],[@CR28]\]. Briefly, up to 10 non-duplicated patient isolates of 10 organism groups including *P. aeruginosa* were collected for three months in 2004 and in 2006 from a total of 100 institutions in 8 geographic regions. MBL-producers were phenotypically identified by the double-disk synergy test using ceftazidime (30 μg) and sodium mercaptoacetate (30 μg) disks (Eiken Chemical, Inc., Tokyo, Japan) following the manufacturer's instructions, and were subjected to further molecular epidemiological investigation \[[@CR29]\]. Ethical approval has been obtained from Toho University School of Medicine Ethics Committee (2511925030).

Antimicrobial susceptibility testing {#Sec9}
------------------------------------

Minimum inhibitory concentrations (MICs) were measured by the broth microdilution method of the Clinical and Laboratory Standards Institute (CLSI) \[[@CR30]\]. The antimicrobial agents tested were as follows: piperacillin sodium salt, ceftazidime hydrate, aztreonam, imipenem monohydrate, amikacin sulfate salt, ciprofloxacin hydrochloride monohydrate (Sigma-Aldrich Japan KK., Tokyo, Japan), cefepime hydrochloride (Bristol-Myers Squibb. Tokyo, Japan), and arbekacin sulfate salt (Meiji Seika Pharma Co., Ltd. Tokyo, Japan). The antimicrobial concentration ranges were 0.06 - 128 μg/ml except for ciprofloxacin (0.25 - 512 μg/ml). MICs were interpreted as susceptible (S), intermediate (I), or resistant (R) according to CLSI interpretive criteria where available \[[@CR31]\].

MDRP was defined as strains with non-susceptibility to at least 1 agent in ≥3 antimicrobial categories according to the international expert proposal \[[@CR32]\]; amikacin as aminoglycosides, imipenem as antipseudomonal carbapenems, ceftazidime or cefepime as antipseudomonal cephalosporins, aztreonam as monobactams.

Analysis of MBL genes and integron by PCR amplification and nucleotide sequencing {#Sec10}
---------------------------------------------------------------------------------

Genomic DNA was prepared by the Wizard genomic DNA preparation kit (Promega, Madison, WI, USA) according to the manufacturer's recommendations. PCR was performed with Takara ExTaq (Takara Bio, Shiga, Japan). Nucleotide sequencing was performed by a commercial DNA sequencing service (Greiner Bio-one, Tokyo, Japan).

*bla*~MBL~ genes were detected and identified by PCR and nucleotide sequencing using primers for *bla*~IMP~ and *bla*~VIM~ \[[@CR33]\]. *bla*~IMP-1~, *bla*~IMP-10~, and *bla*~IMP-6~ are referred as *bla*~IMP-1~ group because the deduced amino acid sequences of *bla*~IMP-1~ differ by single amino acid from those of *bla*~IMP-10~ and *bla*~IMP-6~. Similarly, *bla*~IMP-11~ and *bla*~IMP-41~ are as *bla*~IMP-11~ group because the deduced amino acid sequences differ by single amino acid. Integrase genes specific for class 1, 2, or 3 integrons were detected by PCR using primers by Shibata *et al.* \[[@CR33]\]. Integron GC arrays were determined by PCR and nucleotide sequencing by primer walking \[[@CR34]\]. According to INTEGRALL nomenclature, novel completely sequenced GCs, namely from a part of 5′-conserved segment (5′CS) to a part of 3′-conserved segment (3'CS), were submitted to INTEGRALL for the attribution of new integron numbers \[[@CR12]\].

Genotyping {#Sec11}
----------

MLST was performed as described by Curran *et al.* \[[@CR3]\]. Pulsed-field gel electrophoresis (PFGE) of *Spe*I-digested DNA fragments from each strain was performed on a CHEF-MAPPER II apparatus (Bio Rad Laboratories, Rockland, Maine, USA) at 6 V/cm, for 19.7 h with pulse times running from 5.3 to 34.9 s in 0.5 × TBE buffer at 14°C. PFGE patterns in the dendrogram were analyzed with Molecular Analyst Software Fingerprinting II (Bio-Rad Laboratories). Only restriction fragments larger than 50 kb were used for analysis. PFGE genotypes were distinguished by the unweighted pair-group method using average linkages (UPGMA) and Dice coefficient, and isolates with ≥80% similarity were assigned into the same pulsotype.

Statistical analyses {#Sec12}
--------------------

Statistical calculations were made using Graph-Pad Prism 5.01 (GraphPad Software Inc.). *P* values were calculated from two-tailed Fisher's exact test for categorical variables, and *P* value \<0.01 was considered as a statistically significant difference.

Nucleotide sequences accession numbers for novel integrons {#Sec13}
----------------------------------------------------------

Genbank/EMBL/DDBJ accession numbers for novel nucleotide sequences in the present study are as follows: AB901034-AB901041 for In826-In833, and AB901042-AB901046 for In991-995, and AB901047 for partial integron of isolate TUM3995.
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